Hims & Hers Health Set for Earnings Beat Despite 80% EPS Drop Forecast

TL;DR: Hims & Hers Health (HIMS) is expected to post a sharp 80% year‑over‑year drop in earnings per share while revenue grows modestly, yet a +36.5% Earnings ESP signals a likely beat of consensus estimates.

Analysts brace for a steep earnings decline at Hims & Hers Health, but the numbers hint at a surprise. The company forecasts quarterly earnings of $0.04 per share, down 80% from the same period last year, while revenue is projected at $619.62 million, up 5.7% year‑over‑year. This contrast between falling profits and rising sales sets up a classic earnings‑surprise scenario.

The Zacks Earnings ESP of +36.49% measures the gap between the Most Accurate Estimate—a recent analyst revision—and the broader Zacks Consensus Estimate. A positive ESP indicates that analysts have recently raised their earnings outlook relative to the consensus, which historically precedes an actual beat about 70% of the time when paired with a Zacks Rank of #3 (Hold). HIMS currently holds that rank, reinforcing the beat probability.

Market data shows HIMS trading near $12 per share in early May 2026, giving it a market capitalization of roughly $2.3 billion. The stock has gained about 4.2% over the past month, outperforming the S&P 500’s 1.8% rise and the telehealth sector’s average 2.1% increase during the same period.

What this means for investors is that, despite the headline earnings decline, the stock could react positively if the actual EPS tops the $0.04 consensus. Management’s commentary on subscriber growth, prescription volume, and cost controls will be key to determining whether any beat translates into longer‑term confidence.

Investors will watch the May 11 earnings release and subsequent management guidance for clues on whether the expected surprise sustains upward momentum.